Polyplus-transfection and the US NIH sign research agreement
For non-exclusive access to PEI-based transfection technologies
Polyplus-transfection, a privately-held company developing innovative technologies for molecular and cellular biology, has granted two agencies of the United States National Institutes of Health (NIH) a non-exclusive, research licence to use Polyethylenimine (PEI) for in vitro transfection applications. The two agencies are the National Institute of Allergy and Infectious Diseases (NIAID) and the National Cancer Institute (NCI).
No financial details have been released.
The NIAID and the NCI have become two of Polyplus’ growing number of sub-licensees who have acquired rights to use PEI-mediated transfection applications for research purposes.
The company signed a prior use licence and extended supply agreement with Merck for PEI in October 2013.
Polyplus-transfection, based in Strasbourg, France, is the worldwide, exclusive licensee to PEI for transfection applications. Transfection with PEI is said to offer ease of use, high transfection efficiency and excellent viability in the lines of mammalian cells most frequently chosen by scientists working in protein, virus and antibody production.
'Signing this agreement keeps our technology at the forefront of the battle to understand, treat and prevent cancer, as well as other infectious, immunologic and allergic diseases,' said Mark Bloomfield, CEO of Polyplus-transfection. 'The execution of this agreement with the NIH is another demonstration of the strength and significant value of Polyplus’ specific intellectual property rights in PEI-mediated nucleic acid delivery for research purposes.'
